Zai Lab Ltd (ZLAB) Stock
3 of the hedge funds AlphaScala tracks reported ZLAB in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Citadel's at $24.41M. Company insiders reported 0 open-market buys and 3 sales on SEC Form 4 in the 90 days to Oct 21, 2026.
Which hedge funds own ZLAB?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Citadel Ken Griffin | 1.28M | $24.41M | -24% |
| Marshall Wace | 147K | $2.80M | NEW |
| D.E. Shaw David Shaw | 141K | $2.68M | +123% |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are Zai Lab Ltd insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Aug 19, 26 | Chen Yajing | Chief Financial Officer | SELL | 260 | $7K |
| Aug 12, 26 | Lis William | Director | SELL | 8.5K | $213K |
| Aug 11, 26 | Chen Yajing | Chief Financial Officer | SELL | 619 | $15K |
SEC Form 4 filings as of Oct 21, 2026
See cluster-buy signals across all tickers →ZLAB price chart
Powered by TradingViewWhat does Zai Lab Ltd do?
Zai Lab Ltd. is an innovative, commercial-stage biopharmaceutical company based in China and the United States. It focuses on discovering, developing, and commercializing transformative therapies that address significant unmet medical needs in oncology, immunology, neuroscience, and infectious diseases. The company markets several approved products in Greater China, including Zejula, a poly (ADP-ribose) polymerase inhibitor for ovarian cancer; VYVGART, an antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for community-acquired bacterial pneumonia and acute bacterial skin infections; Optune Gio for glioblastoma; Qinlock for gastrointestinal stromal tumors; Xacduro for hospital-acquired bacterial pneumonia; and Augtyro for ROS1-positive non-small cell lung cancer. Zai Lab Ltd. maintains a robust pipeline of investigational therapies, such as zocilurtatug pelitecan, a DLL3-targeted antibody-drug conjugate for small cell lung cancer; ZL-1503, a bispecific antibody for atopic dermatitis; and ZL-6201, an LRRC15 antibody-drug conjugate for solid tumors. As a fully integrated biopharma with in-house R&D, manufacturing facilities for small- and large-molecule drugs, and a specialized commercial organization, Zai Lab Ltd. partners with global innovators to accelerate access to advanced treatments for patients in China and beyond. Founded in 2014 and headquartered in Shanghai, China, and Cambridge, Massachusetts, it plays a vital role in bridging global innovation to high-need markets.